N,N-dimethyltryptamine (DMT), a component of the ayahuasca brew, activates the subgranular zone of the dentate gyrus in the hippocampus, the main adult neurogenic niche, promoting the generation of new neurons. Mice treated with DMT performed better on memory tests than control animals, suggesting a functional relevance for the newly produced neurons. The neurogenic effect appears to involve sigma-1 receptor activation, as a sigma-1 receptor antagonist blocked it. These findings demonstrate that DMT treatment enhances adult neurogenesis and improves spatial learning and memory.
Parkinson's disease involves progressive loss of dopamine-producing neurons in the nigrostriatal pathway, along with brain inflammation. Current medications only manage symptoms. This preclinical study tested N,N-dimethyltryptamine (DMT), the active compound in ayahuasca, which activates serotonin 5-HT2A receptors (causing hallucinogenic effects) and sigma-1 receptors linked to neuroprotection. DMT treatment produced molecular changes in the nigrostriatal pathway indicating reduced neuroinflammation and preserved neurons. Behavioral tests also showed symptom improvement. These results suggest DMT may modify disease progression in Parkinson's disease, supporting further research.